XML 20 R10.htm IDEA: XBRL DOCUMENT v3.25.3
Revenue from Contracts with Customers
 6 Months Ended
Oct. 31, 2025
Revenue from Contract with Customer [Abstract]  
Revenue from Contracts with Customers Revenue from Contracts with Customers
Oncology Revenue
The following table represents disaggregated revenue for the three and six months ended October 31, 2025 and 2024 (in thousands):
Three Months Ended
October 31,		Six Months Ended October 31,
 2025202420252024
Pharmacology services$14,515 $12,498 $27,745 $25,567 
TOS data license revenue157 — 468 — 
Other TOS revenue363 991 817 1,983 
Total oncology revenue$15,035 $13,489 $29,030 $27,550 
Translational Oncology Solutions ("TOS") license revenue represents revenue from the sale of a license to access certain of the Company's PDX data. Other TOS revenue represents additional services provided to the Company's pharmaceutical and biotechnology customers, specifically flow cytometry services and software-as-a-service ("SaaS") provided via our Lumin Bioinformatics software ("Lumin").